Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting

On April 20, 2016 Genmab A/S (Nasdaq Copenhagen: GEN) reported that two daratumumab abstracts have been accepted for presentation at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, June 3 — 7 (Press release, Genmab, APR 20, 2016, View Source [SID:1234511144]). The titles of the abstracts are available on the ASCO (Free ASCO Whitepaper) website at www.asco.org via ASCO (Free ASCO Whitepaper)’s iPlanner. With the exception of the daratumumab Phase III Castor study data, which has been designated as a late breaking abstract by ASCO (Free ASCO Whitepaper), the full abstracts are scheduled to be published on the ASCO (Free ASCO Whitepaper) website on May 18 at 5:00PM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Daratumumab Phase III Castor Study Data
Safety and efficacy data from the Phase III study of daratumumab in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma will be presented in the Plenary Session at the ASCO (Free ASCO Whitepaper) meeting on June 5. A total of 498 patients with relapsed or refractory multiple myeloma were enrolled in the study. The study met the primary endpoint of improving progression free survival (PFS); Hazard Ratio (HR) = 0.39, p<0.0001. The median PFS for patients treated with daratumumab has not been reached, compared to median PFS of 7.2 months for patients who did not receive daratumumab.

Daratumumab showed a manageable safety profile in the study consistent with the reported safety profile of monotherapy and background bortezomib/dexamethasone therapy.

As announced on March 30, 2016 an Independent Data Monitoring Committee recommended stopping the study as the primary endpoint had been reached at the time of the pre-specified interim analysis. Patients originally assigned to the bortezomib plus dexamethasone treatment group will be offered the option of receiving daratumumab following confirmed disease progression. Patients continue to be monitored for safety and overall survival.

Abstract details: Phase 3 randomized controlled study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study— Abstract # LBA4, Oral presentation, Sunday, June 5 at 3:10PM-3:25PM CDT

This abstract has been designated a late breaking abstract and the embargo will be lifted on Sunday, June 5 at 6:30AM CDT.
"ASCO is one of the premier medical conferences of the year and we are very pleased that highly impressive data with one of our key programs, daratumumab, will be presented again this year," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of Further Abstracts to Be Presented

Daratumumab
An open-label, dose-escalation Phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO) — Abstract # 333b, Trials in progress poster presentation, Monday, June 6 at 8:00AM -11.30AM CDT
The study described in this abstract is ongoing.

About DARZALEX (daratumumab)
DARZALEX (daratumumab) injection for intravenous infusion is indicated in the United States for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. For more information, visit www.DARZALEX.com.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. It is believed to induce rapid tumor cell death through programmed cell death, or apoptosis,1,2 and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity,1,2 antibody-dependent cellular phagocytosis3,4 and antibody-dependent cellular cytotoxicity.1,2 In addition, daratumumab therapy results in a reduction of immune-suppressive myeloid derived suppressor cells (MDSCs) and subsets of regulatory T cells (Tregs) and B cells (Bregs), all of which express CD38. These reductions in MDSCs, Tregs and Bregs were accompanied by increases in CD4+ and CD8+ T cell numbers in both the peripheral blood and bone marrow.1

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. Five Phase III clinical studies with daratumumab in relapsed and frontline settings are currently ongoing, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, non-Hodgkin’s lymphoma and a solid tumor indication.

Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research (AACR) Annual Meeting

On April 20, 2016 Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, reported the presentation of preclinical data relating to its KTN0158 drug development program at the AACR (Free AACR Whitepaper) Annual Meeting, taking place in New Orleans, Louisiana, April 16-20, 2016 (Press release, Kolltan Pharmaceuticals, APR 20, 2016, View Source [SID:1234511162]). KTN0158 is a proprietary, clinical-stage, humanized anti-KIT IgG1 monoclonal antibody drug candidate that selectively and potently inhibits KIT and is being developed as a potential therapy for cancer and mast cell-related diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The compelling preclinical data that were presented at AACR (Free AACR Whitepaper) support our plans to evaluate KTN0158 in combination with T-cell checkpoint inhibitors in the clinic near-term. This expands our current clinical focus beyond gastrointestinal stromal tumors (GIST) and further broadens the opportunity to investigate the treatment of cancer patients through targeting KIT, with potential to affect immunosuppressive mast cells and myeloid cells. Developing innovative biologics with a focus on RTKs expressed on innate immune cells is an exciting new area for Kolltan with KTN0158 in clinical development," stated Gerald McMahon, Ph.D., President and Chief Executive Officer of Kolltan.

Rich Gedrich, Ph.D., Senior Director of Translational Medicine of Kolltan, added, "KTN0158 represents a novel approach to inhibit KIT on tumor cells by blocking the dimerization of the receptor through an allosteric mechanism. Previous preclinical data have shown significant anti-tumor activity in KIT-driven tumors such as GIST, targeted in our Phase 1 trial of KTN0158, and now the current findings in combination with anti-PD-1 and anti-CTLA4 antibodies support a second distinct approach to develop KTN0158 as an anti-cancer therapy."

Following are the key data and results from the two presentations at AACR (Free AACR Whitepaper) relating to KTN0158:
On Sunday, April 17, KTN0158 was highlighted as a novel experimental treatment approach for GIST in an oral presentation titled "Experimental Treatment Options for Gastrointestinal Stromal Tumors with Primary or Secondary Resistance to Tyrosine Kinase Inhibitors". The presentation reviewed previously disclosed preclinical data including:

An overview of KTN0158’s unique mechanism of action which inhibits KIT activation by blocking receptor dimerization; and
The preclinical activity of KTN0158 in GIST models with activating KIT mutations and also activity in dogs with spontaneous mast cell tumors driven by KIT activation.

On Tuesday, April 19, "Inhibition of KIT In Vivo Modifies Immune Cell Populations to Improve the Efficacy of Checkpoint Inhibitors in Syngeneic Mouse Tumor Models" (Abstract Number 4020), was presented in a poster session.

The poster presentation reported the following data and results:

Enhanced anti-tumor activity with the combination of a surrogate mouse anti-KIT monoclonal antibody with either anti-PD-1 or anti-CTLA4 monoclonal antibodies in several syngeneic mouse tumor models; and

Mechanistic studies showed a significant decrease in monocytic myeloid-derived suppressor cells (mMDSCs) in the tumor and in the spleen of the anti-KIT antibody treated groups. High levels of circulating mMDSCs have been associated with reduced survival in melanoma patients treated with ipilimumab or nivolumab.

The poster is available on the Kolltan website.

About KTN0158

KTN0158 is a proprietary, humanized monoclonal antibody designed using structure-based approaches to block the activation of KIT, an RTK that is expressed on many cancers and mast cells. There are currently no KIT-targeting antibodies on the market for any disease indication. In oncology, KIT is expressed in tumors such as GIST, melanoma, acute myeloid leukemia (AML), small cell lung cancer (SCLC), and others. Additionally, KIT is expressed in immune suppressive cells in the tumor microenvironment and thus may provide a novel combination treatment for immuno-oncology. Kolltan has initiated a Phase 1 study for the treatment of GIST and other KIT-expressing tumors (NCT02642016) and plans to move into combination studies with other targeted therapies and T cell checkpoint inhibitors.

Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting

On April 20, 2016 Geron Corporation (Nasdaq:GERN) reported two poster presentations of data from non-clinical studies of the telomerase inhibitor, imetelstat, at the 2016 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting held in New Orleans, Louisiana (Press release, Geron, APR 20, 2016, View Source;p=RssLanding&cat=news&id=2158608 [SID:1234511145]). The first poster presentation described results that treating acute myeloid leukemia (AML) cell lines with imetelstat enhanced the effects of agents currently used for the treatment of AML. These data extend the rationale from prior non-clinical studies for the potential use of imetelstat in hematologic myeloid malignancies, such as AML, including in combination with standard therapies. The second poster presentation described results from non-clinical studies that provide further evidence of potential on-target mechanisms of telomerase inhibition by imetelstat underlying the reduction in platelets observed in previously conducted imetelstat clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The non-clinical studies were conducted by scientists at Janssen Research & Development, LLC and academic collaborators under the terms of the exclusive worldwide imetelstat license and collaboration agreement between Geron and Janssen Biotech, Inc. The poster presentations are available on Geron’s website at www.geron.com/presentations.

Impact of hypomethylating agents on hTERT expression and synergistic effect in combination with imetelstat, a telomerase inhibitor, in AML cell lines

AML cells express high levels of the telomerase catalytic subunit (hTERT). The expression of hTERT may be regulated through chemical changes to DNA, known as epigenetic modifications, such as the addition of a methyl group (methylation). Non-clinical studies by various cancer biologists have suggested a correlation between hTERT overexpression and hypermethylation in some cancers. Two compounds that are currently used for the treatment of AML, decitabine and 5-azacitidine, act as hypomethylating agents by inhibiting DNA methylating enzymes. Furthermore, these compounds have been reported to also reduce hTERT expression in AML cells in addition to inhibiting cell growth.

The aim of the non-clinical study in the AACR (Free AACR Whitepaper) poster was to determine whether combining hypomethylating agents and imetelstat can further inhibit AML cell viability in vitro compared with either agent alone. Combination treatment of the AML cell lines with either decitabine or 5-azacitidine followed by imetelstat, resulted in a greater reduction in cell viability or slower recovery of growth, respectively, than when a hypomethylating agent was administered alone. Similarly, when AML cell lines were treated with decitabine or 5-azacitidine followed by imetelstat, apoptosis, or cell death, increased in a dose-dependent manner.

Rusbuldt J, et al. 2016 AACR (Free AACR Whitepaper)

Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors

Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns to trigger innate immune responses. For example, synthetic, single-stranded oligonucleotides with certain properties characteristic of bacteria and virus genomes activate the innate immune response through TLR9 signaling. In addition, TLR activation has been associated with lipopolysaccharide-induced thrombocytopenia in animal models.

The aim of the non-clinical study in the AACR (Free AACR Whitepaper) poster was to test a recent hypothesis that the thrombocytopenia observed in patients with myeloproliferative neoplasms (MPN) treated with imetelstat might occur through off-target effects by binding to and activating TLRs, such as TLR9. Results from the study suggest that the thrombocytopenia associated with imetelstat is not likely to be driven via interactions with TLRs. First, the oligonucleotide imetelstat is shorter and lacks certain features in its sequence required to activate TLR9. Second, in an assay for TLR activity, treatment with imetelstat at clinically relevant concentrations had no stimulatory effect on the majority of TLRs tested, including TLR9. Although a small induction of TLR8 was observed in the assay, such activity was not believed to be relevant because the induction was substantially lower than the positive control used in the experiment, and TLR8 has not been reported to be associated with thrombocytopenia.

The poster also cites results from previous non-clinical studies which suggest potential on-target mechanisms of telomerase inhibition for the observed thrombocytopenia in patients treated with imetelstat. Since telomerase activity is required for the differentiation of megakaryocyte progenitors into mature platelet-producing cells, previous ex vivo studies used cells taken from MPN patients and healthy individuals to show that treatment with imetelstat decreases hTERT expression and inhibits telomerase activity, which is concurrent with blocking the terminal maturation of normal megakaryocyte precursors, reducing the number of mature megakaryocytes available to produce platelets. Other prior ex vivo studies also included in the poster showed that imetelstat selectively inhibits the proliferation of malignant megakaryocyte progenitors from patients with essential thrombocythemia compared to normal progenitors from healthy individuals, suggesting that imetelstat may regulate telomerase differently in malignant versus normal cells.

Baerlocher GM, et al. 2016 AACR (Free AACR Whitepaper)

About Imetelstat

Imetelstat (GRN163L; JNJ-63935937) is a potent and specific inhibitor of telomerase that is administered by intravenous infusion. This first-in-class compound, discovered by Geron, is a specially designed and modified short oligonucleotide, which targets and binds directly with high affinity to the active site of telomerase. Preliminary clinical data suggest imetelstat has disease-modifying activity by inhibiting the progenitor cells of the malignant clones associated with hematologic myeloid malignancies in a relatively select manner. Most commonly reported adverse events in imetelstat clinical studies conducted previously by Geron included fatigue, gastrointestinal symptoms and cytopenias. Patients in those studies also experienced elevated liver enzymes, which resolved to normal or baseline in the majority of patients after imetelstat treatment was withdrawn. Imetelstat has not been approved for marketing by any regulatory authority.

About the Collaboration with Janssen

On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of the agreement, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities are being managed through a joint governance structure, with Janssen responsible for these activities.

Janssen is conducting two imetelstat clinical trials: a Phase 2 clinical trial in patients with intermediate-2 and high risk myelofibrosis (MF) and a Phase 2/3 clinical trial in patients with low and intermediate-1 risk myelodysplastic syndromes (MDS). For more information about these clinical trials, please visit www.clinicaltrials.gov.

Kolltan Pharmaceuticals Presents Preclinical Data at the 2016 American Association for Cancer Research (AACR) Annual Meeting

On April 20, 2016 Kolltan Pharmaceuticals, Inc., a privately held clinical-stage company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for use in oncology and immunology, reported the presentation of preclinical data relating to its KTN3379 and KTN0073 drug development programs at the AACR (Free AACR Whitepaper) Annual Meeting, taking place in New Orleans, Louisiana, April 16-20, 2016 (Press release, Kolltan Pharmaceuticals, APR 20, 2016, View Source [SID:1234511164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This new preclinical data with KTN3379, along with emerging clinical results to date, support our plans to initiate a Phase 2 study in squamous cell tumors of the head and neck. Separately, we have identified KTN0073 as a unique antibody targeting the Met receptor tyrosine kinase with novel mechanisms of action. We are actively seeking a partner for the KTN0073 program to assist in the development of this novel and differentiated antibody drug candidate," stated Gerald McMahon, Ph.D., President and Chief Executive Officer of Kolltan.

"KTN3379 has shown broad anti-tumor activity in preclinical models, is potent, and binds to a unique epitope on ErbB3 or HER3. We presented scientific data supporting the potential use of KTN3379 for treatment of squamous cell tumors of the head and neck (HNSCC) and we continue to explore additional tumor indications where ErbB3 plays a role in driving the tumor or limiting therapies due to pathway resistance. The data presented shows anti-tumor activity of KTN3379 in HNSCC models in combination with the standard of care, cetuximab and radiation, and the anti-tumor activity correlated with several measurable parameters related to activation of the ErbB3 or EGF receptors. HNSCC cancer enriches for these parameters, and we are measuring these endpoints in ongoing and future clinical studies to guide patient selection and drug effectiveness," said Theresa LaVallee, Ph.D., Senior Vice President, Translational Medicine and Product Development at Kolltan.

Following are key data and results from the four poster presentations at AACR (Free AACR Whitepaper) relating to KTN3379 and KTN0073:

KTN3379
KTN3379 is an IgG1 monoclonal antibody that effectively locks ErbB3 in an inactive conformation by binding to a unique epitope, which may contribute to the antibody’s high potency and dual mechanism of action.

On Monday, April 18, "Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN" (Abstract Number 1196) was presented in a poster session.

The poster presentation reported the following data and results:

ErbB3 and its ligand neuregulin (NRG) are highly expressed in HNSCC and HER2, not EGFR, catalyzes ErbB3 activation in the presence of NRG;

Database analyses of HNSCC patient samples indicated that NRG expression is highly correlated with the expression of the EGFR ligands amphiregulin (AREG) and transforming growth factor α (TGFα), but not other EGFR ligands;

Using NRG-positive cell lines, KTN3379 anti-tumor activity correlated with the level of secreted AREG and TGFα and EGFR homodimer levels; and

The combined measurement of NRG with EGFR activation is a potential biomarker for KTN3379 activity.
On Tuesday, April 19, "Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC" (Abstract Number 2979) was presented in a poster session.

The poster presentation featured the following data and results:

Combined administration of KTN3379 and BYL719, a PIK3Cα inhibitor, enhanced anti-tumor activity over single agent administration in HNSCC models;

Inhibition of PI3K led to upregulation of ErbB3 activity;

ErbB3 upregulation attenuated PI3K inhibition suggesting ErbB3 is playing a role in resistance as a compensatory pathway; and
Dual targeting of the ErbB3 and PI3K pathways led to synergistic anti-tumor activity in vitro and in vivo.

On Tuesday, April 19, "Inhibition of heregulin-mediated ErbB3 signaling as a radiosensitization therapy for head and neck cancers" (Abstract Number 3053) was presented in a poster session.

The poster presentation reported the following data and results:

Two different HNSCC models of cetuximab resistance were generated using A431 and FaDu cell lines by exposure to increasing doses of cetuximab over 14 weeks;

In these models, ErbB3 levels and signaling were upregulated and KTN3379 effectively blocked elevated ErbB3 signaling and overcame the cetuximab resistance in the A431 and FaDu models;

In a panel of six HNSCC cell lines, KTN3379 enhanced the anti-tumor activity of radiation alone or the combination of radiation and cetuximab in most of the cell lines; and

These results suggest that combining KTN3379 with standard of care treatments in HNSCC, including cetuximab and radiation, may enhance anti-tumor activity and may overcome resistance.

KTN0073
KTN0073 is a humanized, IgG2 monoclonal antibody that inhibits Met-dependent tumor growth in preclinical models when activated by HGF, Met gene amplification, or mutations in exon 14.

On Tuesday, April 19, "An anti-Met IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth" (Abstract Number 3835) was presented in a poster session.

The poster presentation highlighted the following data and results:
KTN0073 was identified as a potent anti-Met antibody with broad anti-tumor activity in HGF-driven and Met amplified tumors;

KTN0073 induced potent degradation of oncogenic exon 14-mutant Met, which propagates prolonged Met signaling due to a defect in receptor degradation;

Conversion of the antibody from IgG1 to IgG2 surprisingly resulted in enhanced anti-tumor activity in vitro and in vivo; and

KTN0073 demonstrated broad anti-tumor activity through multiple mechanisms of action in HGF-driven, Met-amplified, and exon 14-mutated tumors.

The posters are available on the Kolltan website.

About KTN3379
KTN3379 is a human monoclonal antibody designed to block the activity of ErbB3 (HER3), a receptor tyrosine kinase (RTK) that belongs to the epidermal growth factor receptor, or EGFR, family. ErbB3 is believed to be an important receptor regulating cancer cell growth and survival. ErbB3 is expressed in many cancers, including head and neck, breast, lung, gastric, and melanoma. Kolltan is conducting multiple clinical trials evaluating KTN3379 in the treatment of solid tumors (NCT02014909, NCT02456701, and NCT02473731).

Checkmate Pharmaceuticals Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer and Announces Dosing of First Patient in Immuno-Oncology Phase 1b Trial with CMP-001, a TLR9 Agonist

On April 20, 2016 Checkmate Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing novel approaches for cancer immunotherapy, reported the appointment of David Mauro, M.D., Ph.D . to the newly created position of Chief Medical Officer. Checkmate also announced the dosing of the first patient in a Phase 1b trial with CMP-001 in combination with pembrolizumab in melanoma patients who have either progressed on or failed to respond to at least 12 weeks of anti -‐ PD1 therapy. CMP -‐ 001 is a first -‐ in -‐ class CpG -‐ A oligonucleotide that activates the innate immune system via Toll -‐ like receptor 9 (TLR9) (Press release, Checkmate Pharmaceuticals, APR 20, 2016, View Source [SID1234516800]). The combination therapy has the potential to increase the proportion of cancer patients who respond to checkpoint inhibitor therapies and to increase the magnitude and duration of the anti -‐ tumor responses , providing added clinical benefit . Industry Veteran with Immun o -‐ Oncology Clinical Development and Leadership Expertise Dr. Mauro brings to Checkmate more than 15 years of experience in early and late stage oncology drug development, clinical and translational research , and medical affairs. Previously he served as Exe cu tive Vice President and Chief Medical Officer at Advaxis , where he was responsible for the strategy and oversight of the company’s clinical programs, including several combination drug programs with checkpoint inhibitor s . "We welcome David to the Checkmate team at this pivotal time ," said Art Krieg, M.D., Chief E xecutive Officer of Checkmate. " His deep knowledge and experience in immuno -‐ oncology , and specifically in the development of checkpoint inhibitor combinations, will be invaluable to Checkmate in the clinical development of CMP -‐ 001 for patients with advanced cancer ." Dr. Mauro has held senior level positions at Merck & Co. and Bristol Myers Squibb Company, where he was involved in the clinical development, trans la tional science , and life cycle management for multiple programs , including Keytruda ( pembrolizumab ), Erbitux (cetuximab), Sprycel (dasatinib), and Sylatron (peginterferon alfa -‐ 2b). He received his Bachelor of Science in Bioch emistry from Cornell University, his medical degree and his doctorate in pharmacology from Temple Univ ersity School of Medicine , and completed his residency training at the National Cancer Institute. A s Chief Medical Officer at Checkmate, Dr. Mauro will oversee the development of the Company’s current and future clinical programs, based on the TLR9 mechani sm of immune activation. " I am excited to be joining Checkmate as it progress es CMP -‐ 001 into the clinic in itially in melanoma patients ," said Dr. Mauro. "I look forward to working with the team to further expand the development of this compound in other indications and checkpoint inhibitor combinations . The immun o -‐ oncology field is evolving rapidly , and I believe that CMP -‐ 001 has the potential to increase the response rates to current checkpoint therapies a nd have a broad impact in the development of new standards of care f or oncology treatment." Initiation of Phase 1b Trial in Advanced Melanoma with a TLR9 Immune Activator Checkmate has dosed the first patient in its Phase 1b clinical study of CMP -‐ 001 . Th e trial is designed as a multi -‐ center, open -‐ label study of CMP -‐ 001 in combination with pembrolizumab for patients with advanced melanoma who have either progressed on an anti -‐ PD1 , or have failed to respond to at least 12 weeks of therapy . Patients will c ontinue on the approved dose and schedule of pembrolizumab, with the addition of intratumoral CMP -‐ 001 therapy. The trial will include a dose escalation study and will enroll patients in an expansion phase , as well as undertake correlative studies to characterize the immune effects of treatment in the blood and tumor. P atients will be monitored for safety and tolerability as well as possible clinical response . " We are excited to begin our clinical development of this new appr oac h of a ltering the tumor microenvironment with intratumoral CMP -‐ 001," said Dr. Krieg. " We believe this treatment should convert "cold" tumors , which lack immune activation and are not likely to respond to checkpoint inhibitors , in to immunologically "hot" tumors which are much more likely to respond to checkpoint inhibition . This has the potential to induce a powerful anti -‐ tumor CD8 + T cell immune response resulting in significantly increased response rates to checkpoint inhibitor therapy in multiple cancer indications ." About CMP -‐ 001 CMP -‐ 001 comprises a CpG -‐ A oligonucleotide packaged within a virus -‐ like particle . It is designed to activate the innate immune system via Toll -‐ like receptor 9 (TLR9) and mediate tumor control by the subsequent induction of both innate and adaptive anti -‐ tumor immune responses . CMP -‐ 001 is the only CpG -‐ A oligonucleotide in clinical development . It differs from the other major classes of TLR9 agonists in development , CpG -‐ B, and CpG -‐ C , by it s induction of much higher levels of type I interferons, without inducing immune suppressive IL -‐ 10. In addition, the virus -‐ like particle nature of CMP -‐ 001 will promote formation of immune complexes within tumors, providing an additional mechanism driving anti -‐ tumor i mmunity. In preclinical models , CMP -‐ 001 shows single agent activity in controlling growth of both local and distant tumors, with increased anti -‐ tumor ac tivity seen in combination with systemic anti -‐ PD -‐ 1 therapy. CMP -‐ 001 was licensed from Kuros Biosciences AG and was formerly known as CYT003. It has previously demonstrated a good safety profile and evidence of immune activity in over 700 patients who participated in clinical trials for non -‐ oncology indications.
About Checkmate
Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging its expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating a n approach that will combine the ability of CpG DNA to activate an anti -‐ tumor T cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response .
Checkmate’s founder and CEO, Dr. Art Krieg, discovered immune stimulatory CpG DNA in 1994 . S ince then , CpG containing DNA therapies have been administered to thousands of patients showing potent immune activation and a n acceptable safety profile. Checkmate is a privately held company headquartered in Cambridge, M A , whose Series A investors include Sofinnova Ventures and venBio

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!